Role of CMR Imaging in Risk Stratification for Sudden Cardiac Death  by AlJaroudi, Wael A. et al.
a
C
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 6 , N O . 3 , 2 0 1 3
© 2 0 1 3 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 2 . 1 1 . 0 1 1S T A T E - O F - T H E - A R T P A P E R
Role of CMR Imaging in Risk Stratification for
Sudden Cardiac Death
Wael A. AlJaroudi, MD, Scott D. Flamm, MD, MBA, Walid Saliba, MD,
Bruce L. Wilkoff, MD, Deborah Kwon, MD
Cleveland, OhioJACC: CARDIOVASCULAR
IMAGING CME
CME Editor: Ragavendra R. Baliga, MD
This article has been selected as this issue’s CME activity,
available online at http://imaging.onlinejacc.org by select-
ing the CME tab on the top navigation bar.
Accreditation and Designation Statement
The American College of Cardiology Foundation
(ACCF) is accredited by the Accreditation Council
for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.
The ACCF designates this Journal-based CME
ctivity for a maximum of 1 AMA PRA Category 1
redit(s)™. Physicians should only claim credit commen-
surate with the extent of their participation in the activity.
Method of Participation and Receipt of
CME Certificate
To obtain credit for this CME activity, you must:
1. Be an ACC member or JACC: Cardiovascular
Imaging subscriber.
2. Carefully read the CME-designated article available
online and in this issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3
questions provided must be answered correctly to
obtain CME credit.Manuscript received October 14, 2012; revised manuscript received No5. Claim your CME credit and receive your certificate
electronically by following the instructions given at the
conclusion of the activity.
CME Objective for This Article: At the end of this
activity the reader should be able to: 1) recognize the
presence of a possible link between myocardial scar
and sudden cardiac death in patients with various
cardiomyopathies; 2) recognize the role of cardiac
magnetic resonance imaging in the risk assessment
of sudden cardiac death; and 3) recognize the po-
tential role of cardiac magnetic resonance imaging as
a risk-stratifying tool to guide appropriate, effective,
and efficient therapy.
CME Editor Disclosure: JACC: Cardiovascular Im-
aging CME Editor Ragavendra R. Baliga, MD, has
reported that he has no relationships to disclose.
Author Disclosure: Dr. Wilkoff has served on physi-
cian advisory boards for Medtronic, St. Jude Medical, and
Spectranetics and holds a financial interest in Medtronic.
All other authors have reported that they have no rela-
tionships relevant to the contents of this paper to disclose.
Medium of Participation: Print (article only);
online (article and quiz)
CME Term of Approval:
Issue Date: March 20134. Complete a brief evaluation. Expiration Date: February 28, 2014
From the Heart and Vascular Institute, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
Please note that Dr. AlJaroudi is currently affiliated with the Division of Cardiovascular Medicine, American University of
Beirut Medical Center, Beirut, Lebanon. Dr. Wilkoff has served on physician advisory boards for Medtronic, St. Jude Medical,
and Spectranetics and holds a financial interest in Medtronic. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.vember 19, 2012, accepted November 26, 2012.
w

a
o
H
e
b
E
m
a
t
c
c
v
s
w
c
d
s
t
l
i
w
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 3 , 2 0 1 3
M A R C H 2 0 1 3 : 3 9 2 – 4 0 6
AlJaroudi et al.
CMR and Sudden Cardiac Death
393Role of CMR Imaging in Risk Stratification for Sudden Cardiac Death
Left ventricular ejection fraction as determined by echocardiography has a limited sensitivity in predicting
risk for sudden cardiac death (SCD). Subsequent efforts to improve cost-effectiveness of device implanta-
tion and identify a better risk-stratifying tool have been quite desirable. The presence of scar andmyocar-
dial tissueheterogeneity hasbeen linked to ventricular arrhythmia,which is believed tobe themajor cause
of SCD. Cardiac magnetic resonance is a noninvasive imagingmodality that visualizes and quantifies scar,
with growing evidence delineating its additive value in identifying patients at higher risk for SCD. (J Am
Coll Cardiol Img 2013;6:392–406) © 2013 by the American College of Cardiology Foundationo
f
tT
he use of implantable cardiac defibrillator
(ICD) for prevention of sudden cardiac death
(SCD) remains on the rise. Although the
guidelines recommend an ICD for patients
ith left ventricular ejection fraction (LVEF)
35% (1), less than one-third receive an appropri-
te shock (2). The limited sensitivity and specificity
f LVEF to predict SCD has been highlighted (3).
ence, subsequent efforts to improve cost-
ffectiveness of device implantation and identify a
etter risk-stratifying tool have been quite desirable.
vidence suggests that the presence and extent of
yocardial tissue heterogeneity with regions of scar
nd interstitial fibrosis provide a substrate for ven-
ricular arrhythmias that is believed to be the major
ause of SCD, both in ischemic (ICM) and nonis-
hemic cardiomyopathy (NICM) (4).
Cardiac magnetic resonance (CMR) is a nonin-
asive imaging modality that visualizes myocardial
car with late gadolinium enhancement (LGE),
ith proven histopathological correlation (5,6). Be-
ause of its high spatial resolution, it differentiates
ifferent scar patterns and detects areas with inter-
titial fibrosis or edema with T1- and T2-mapping
echniques (7–10). There is growing evidence de-
ineating the strength and additive value of CMR in
dentifying patients at risk for SCD (Tables 1 to 3),
hich will be the focus of this review.
Evaluation of Scar
One of the great successes with CMR is its ability
to visualize myocardial scar. The technique of LGE
was developed more than 1 decade ago and vali-
dated with histopathologic correlation (11,12).
Gadolinium (Gd) is injected intravenously and
diffuses outside the intravascular space but cannot
cross intact myocardial cellular membrane. How-
ever, in areas with myocardial cell damage, there isincreased distribution/unit volume. Gadolinium al-
ters the T1-relaxation properties of the surrounding
tissue, which appears bright on delayed imaging
(11–13). The geographic distribution of LGE helps
distinguish different types of cardiomyopathy. In
addition, quantification of LGE is feasible and
performed with semi-quantitative or automated
measurements (although manual segmentation is
still required) including full-width-at-half-maximal
(14) and/or different SD thresholds of the mean
signal intensity (SI) of remote myocardium in the
same slice (15,16).The infarcted myocardium can
be divided into: 1) core infarct zone; 2) gray or
peri-infarct zone; and 3) total infarct  core 
peri-infarct zones. The core and peri-infarct areas
have been defined as areas with LGE SI 3 SD,
and 2 SD  SI3 SD, respectively (with SD), as
area 50% of the maximal SI of the infarct, and
with SI maximum SI of myocardium but 50%
f maximal SI of the infarct, respectively (with
ull-width-at-half-maximal) (14 –16). However,
here is no consensus on agreed definitions.
Ischemic Cardiomyopathy
CMR quantifies LVEF and mass, which are inde-
pendent predictor of ventricular arrhythmias (17).
Also, the presence and extent of LGE in ICM
(Figs. 1 and 2) correlate with outcomes (Table 2)
(16,18–23).
Review of the published data revealed 7 studies
(pooled number of patients 574, mean event rate/
study approximately 20) with different endpoints
(Table 2). Although LGE was associated with
worse outcomes, 2 studies presented unadjusted
data (18,20), whereas the rest adjusted for ejection
fraction (EF), left ventricular (LV) volumes, func-
tional class, and indication for ICD. Although there
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VT ventricular tachycardia
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394was consensus about the prognostic value of scar,
there was disagreement with regard to which type
of scar was most predictive. Although some studies
showed total scar or core-infarct as most predictive
of endpoints (16,18,20,22), others showed that only
peri-infarct was (19,21,23). The heterogeneity in
scar tissue is thought to create electrical dispersion
and areas of slow conduction that are substrate for
electrical re-entry and malignant arrhythmia (24).
By contrast, data from the Duke group showed that
the extent of total scar (cutoff 5% LV mass) was
the most important parameter in patients
with ICM and NICM (22) and, interest-
ingly enough, similar to the cutoff value of
4.8% by Assomull et al. (25) (NICM
cohort). Although speculative, these find-
ings could suggest that a certain “critical”
LV scar volume is needed for re-entry
ventricular tachycardia (VT) (26). In
addition to the extent of scar, the num-
ber of separate scarred areas was also an
independent predictor of outcomes
(hazard ratio [HR]: 1.7, 95% confidence
interval [CI]: 1.1 to 2.5) (22).
Although these studies showed that
LGE is a prognostic marker of SCD or
ventricular arrhythmia, what matters
most is whether CMR can guide the
decision-making process. Klem et al.
(22) elegantly attempted to answer this
question by analyzing their cohort of
patients that included a wider range of
LVEF. Indeed, their study showed that
patients with LVEF 30% (and simi-
larly with a cutoff value of 35%) and
significant scar (5%) had higher risk
than those with minimal scar (HR: 6.3,
95% CI: 1.4 to 28) but similar to those
with EF 30%; by contrast, those with
EF 30% and minimal scar (5%) had
similar risk to those with EF 30% and
resulted in net reclassification index of
32%. Such stratification is relevant when
eighting the risk-benefit ratio and deciding on
CD placement and potentially might provide
etter use of resources. Such strategy needs to be
valuated prospectively in larger cohorts with
ore events before being adopted by the
uidelines.
There are several limitations to these studies. First,
t is important to emphasize that the reclassification
esults of Klem et al. (22) were based on the composite
se
thy
athy
ion
larndpoint of all-cause death and ICD therapy, whichas the primary endpoint, whereas SCD or ICD
herapy was a secondary endpoint. It is always harder
o interpret results on the basis of composite end-
oints. The small number of events is perhaps the
eason why many of these studies have used such a
trategy. Still, the largest study had 30 total events,
hich potentially makes most models over-fitted.
lso, the quantification of scar throughout studies was
erformed with different techniques. Furthermore, the
ndpoints were neither uniform nor interchangeable.
nducible VT, which was the primary endpoint of 2
tudies, might not be a good endpoint, because a
egative study is often not reassuring (27); indeed,
lem et al. (22) showed in a subgroup analysis that
GE was more predictive of death or ICD therapy
han electrophysiologic study. The more clinically
mportant endpoints, such as SCD or ICD shock for
entricular fibrillation or very fast VT, were limited in
umbers. Finally, the role of CMR in risk-stratifying
atients might be less important for secondary pre-
ention as compared with primary prevention, and
tratification results on the basis of the ICD indication
ere unclear in all but 1 of the studies (16) (Table 2).
NICM
NICM is characterized by LV systolic dysfunction
in the absence of significant coronary artery disease
(CAD). Contributing etiologies include idiopathic
dilated (DCM), hypertrophic (HCM), infectious,
infiltrative, neuromuscular, postpartum, and Tako-
Table 1. Strengths of CMR in Risk Stratiﬁcation of
Sudden Cardiac Death
Noninvasive Imaging Modality
No radiation burden
No iodinated contrast
Quantiﬁcation of left ventricular ejection fraction
Quantiﬁcation of left ventricular volume indexes
Evaluation of right ventricular pathology such as
arrhythmogenic ventricular dysplasia
Evaluation and quantiﬁcation of iron overload in suspected
hemochromatosis
Differentiation of types of cardiomyopathy (ischemic,
nonischemic, and inﬁltrative)
Visualization and quantiﬁcation of scar
Core infarct; peri-infarct, total scar
Area of no-reﬂow in ischemic cardiomyopathy
Interstitial ﬁbrosis (T1-mapping)
Tagged CMR or strain encoded imaging
Evaluation for anomalous coronary arteries
CMR  cardiac magnetic resonance.A B B R E V I A T I O N S
A N D A C R O N YM S
ARVD arrhythmogenic
ventricular dysplasia
CAD coronary artery disea
CI confidence interval
CMR cardiac magnetic
resonance
DCM dilated cardiomyopa
EF ejection fraction
Gd gadolinium
HCM hypertrophic
cardiomyopathy
HR hazard ratio
ICD implantable cardiac
defibrillator
ICM ischemic cardiomyop
LGE late gadolinium
enhancement
LV left ventricular
LVEF left ventricular eject
fraction
MRImagnetic resonance
imaging
NICM nonischemic
cardiomyopathy
RV right ventricle/ventricu
SCD sudden cardiac death
SI signal intensitytsubo cardiomyopathy.
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395DCM. Although most patients with DCM have
angiographically normal coronary arteries or mini-
mal CAD, it is not uncommon to have LGE on
CMR imaging (Fig. 3). Indeed, Gao et al. (16)
showed that up to 71% of patients have scar with
mid-wall pattern and less commonly epicardial
pattern; however, subendocardial injury was con-
comitantly seen in 17% of patients and attributed to
an embolic event.
Review of the published data revealed 7 studies
(pooled number of patients 536, mean events/study
approximately 13) with different surrogate end-
points (Table 3) (16,22,23,25,28–30). All studies
(but 1, which was a subgroup analysis [16]) showed
that scar (total or peri-infarct) was an independent
predictor of endpoints (1 study used unadjusted
event rates [30]) (Table 3). Although the presence
of LGE had prognostic value, the extent of scar
(whether its transmurality [28] or percentage LV
mass [approximately 5%] [22,25]) was most predic-
tive of outcomes.
The most important limitations of these studies
were the different outcomes used (each with its own
clinical weight) giving less room for pooled analysis.
Integrating such data in daily practice remains far
from being adopted by the guidelines with the
current level of evidence.
HCM. SCD is a common cause of death in pa-
tients with HCM. Interventricular thickness 3
Table 2. Summary of Studies Evaluating Role of CMR in Risk St
Endpoint Year n Method
Inducible VT on EPS 2005 48 LGE (2 SD)
2007 47 LGE: FWHM pe
Ventricular arrhythmia or
ICD therapy
2011 55 LGE: SD&FWHM
scar & peri-in
2009 91 LGE: FWHM To
& peri-infarc
Composite endpoint:
ICD therapy or SCD
2012 59 LGE: SD&FWHM
scar & peri-in
*2012 137 LGE (% LV mas
2012 137 LGE: FWHM pe
*Study included patients with ischemic cardiomyopathy (ICM) and dilated cardi
Implantable cardiac deﬁbrillator (ICD) therapy or sudden cardiac death (SCD) was
on the Cox proportional hazard (CPH) model. †Of the 18 events, 12 were for a
AUC  area under the curve; CMR  cardiac magnetic resonance; EDV  end-
hs-CRP  high-sensitivity C-reactive protein; LGE  late gadolinium enhancem
tachycardia.cm, unexplained syncope, family history of SCD,resting LV outflow gradient 30 mm Hg, and
sustained VT have been identified as risk factors
for SCD. Myomectomy and transcoronary alco-
hol septal ablation are the treatment of choice to
relieve the LV outflow obstruction and improve
symptoms. Although myomectomy has been
shown to reduce risk of SCD (31), the long-term
outcomes with alcohol septal ablation remain
controversial (32,33).
LV mass index and maximal LV wall thickness
have been predictive of SCD (34). If untreated,
HCM might progress to a “burned out” state and
evolve into dilated ventricle mimicking DCM (35).
Myocardial fibrosis is frequently identified (Figs. 1
and 4) and is a strong predictor for SCD (Table 3).
There are 5 different studies, including 1 meta-
analysis (pooled number of patients 1,915; 30 SCD;
and 36 cardiac deaths), that showed LV scar as an
independent predictor of inducible VT (unadjusted)
(36), SCD (37,38), or cardiac death (37,39). In the
largest and most current international studies (n 
594), Chan et al. (38) showed that the extent of
LGE was independently associated with increased
risk for SCD even after controlling for traditional
clinical risk factors (adjusted odds ratio: 1.25/5%
LGE increase, p  0.002). This is clinically rele-
vant when making a decision about implanting an
ICD in patients who would be falsely labeled as
lower risk on the basis of clinical features alone. In
ying for SCD in ICM
Events (n) Results
18 Unadjusted logistic regression (model with
performed better than EF); More VT wit
infarct mass, p  0.0005
arct 20 Adjusted regression model for infarct, EF,
Higher peri-infarct size associated with
inducible VT, p  0.015
tal
t
14 Receiver-operating curve; Total scar: AUC
p  0.01 Peri-infarct: p  NS
car 18† CPH model, adjusted for EF and infarct siz
infarct: HR: 1.49/10 g [1.01–2.20], p  0
Infarct core: p  NS
tal
t
10 CPH model, adjusted for indication of ICD
insertion; Total scar: HR: 3.7 [1.1–12.1],
NPV 86% Peri-infarct: p  NS
30 CPH model adjusted for EF, scar size and
Scar size (5% LV mass): HR: 4.8 [1.6–1
p  0.004
arct 27 CPH model adjusted for diuretic use, infar
hs-CRP; Peri-infarct: HR: 4.6 [1.4–15] (3rd
vs.1st), p  0.01
pathy (DCM) (no mention what percentage was each category) and variable rang
secondary endpoint; all-cause death or ICD therapy was the primary endpoint (39 e
sine triphosphate therapy, whereas the rest were for ICD shock.
olic volume; EPS  electrophysiology study; FWHM  full width half maximum m
V  left ventricle; NYHA  New York Heart Association functional class; Ref  reratif
s Ref. #
infarct
h large
(18)
ri-inf and EDV; (19)
To
farc
0.75, (20)
tal s
t
e; Peri-
.04;
(21)
To
farc p  0.03,
(16)
s) NYHA;
3.7],
(22)
ri-inf ct, and
tertile
(23)
omyo e of ejection fraction (EF).
the vents) with similar results
deno
diast ethod; HR  hazard ratio;
ent; L ference; VT  ventricularfact, Chan et al. (38) showed that 8 of 11 patients
other abbreviations as in T
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396with SCD do not have clinical risk factors. By
contrast, the absence of LGE was associated with a
low likelihood of adverse events (adjusted odds
ratio: 0.59, 95% CI: 0.34 to 0.99), and perhaps the
decision to place an ICD might be deferred in this
group.
Myocarditis. Myocarditis is an acute or chronic in-
flammatory disease of the myocardium triggered by
infectious agent or chemotherapy. Most cases in
North America and Europe are viral in etiology but
commonly protozoan-mediated in South America.
The involvement of the right ventricle (RV) has
been identified as risk for SCD (40). The role of
CMR in risk-stratifying patients has been recently
investigated in 203 consecutive patients with biopsy
proven viral myocarditis (41). CMR visualizes scar
on LGE (commonly with a nonischemic distribu-
Studies Evaluating Role of CMR in Risk Stratifying for SCD in NIC
Endpoint Year n Events (n)
Inducible VT 2005 26 5
ICD therapy 2011 61 9
ICD therapy or SCD 2012 65 8
2012 81 18
2012 137 30
SCD† or sustained VT 2006 101 7
Hosp. for HF, ICD
therapy, or cardiac
death
2008 65 15
Inducible VT 2010 38 12
SCD 2012 1,063 30
2012 594 11
Cardiac death 2012 1,063 36
2010 220 16 (11 had SCD)
SCD or cardiac death 2012 203 33 cardiac death
18 SCD
All-cause death or
SCD
2005 51 16 (11 SCD; 5 HF)
Cardiac death 2009 81 5
All-cause death or
ICD therapy
2011 76 8
ic cardiomyopathy (NICM) and ICM (no clear mention what percentage of each
iomyopathy; HF  heart failure; Hosp  hospital stay; KM  Kaplan Meier; LV  l
able 2.tion pattern) (Fig. 5) and tissue edema in the acutephase with T2-STIR or T2-mapping (a newer
technique that is less prone to coil sensitivity and
artifacts, more reproducible, but still under inves-
tigation as a research tool). In the study by Grun
et al. (41), none of the patients without LGE had
SCD (negative predictive value 100%), irrespec-
tive of LVEF or LV volumes. Hence, the absence
of LGE might identify patients at low risk for
SCD who do not warrant an ICD despite a low
EF and can be followed-up clinically. Large
prospective studies are warranted to validate these
findings.
Data on other types of myocarditis, particularly
giant-cell myocarditis are lacking. Case reports have
shown evidence of inflammation, granuloma, and
fibrosis on autopsy in patients who had SCD (42).
The role of CMR in this population remains to be
Results Ref. #
Logistic regression model adjusted for LVEF 26%–75%
transmurality scar: OR 9.1, p  0.02
(28)
Unadjusted KM curves. No CPH or regression analysis
LGE vs. LGE: 29% vs. 0% event rate, p  0.04
(29)
CPH model adjusted for indication of ICD insertion
Total scar: HR: 1.8 [0.4–7.6], p  0.4
(16)
CPH model adjusted for diuretic use, infarct, and hs-
CRP Peri-infarct: HR: 4.6 [1.4–15] (3rd tertile vs.1st),
p  0.01
(23)
CPH* model adjusted for EF, scar size, and NYHA class
Scar size (5% LV mass): HR: 4.8 [1.6–13.7], p 
0.004
(22)
CPH model adjusted for EF Scar 4.8%: HR: 5.9
[1.1–32.2], p  0.04
(25)
CPH model adjusted for LV volume index and
functional class LGE: HR: 8.2 [2.2–31], p  0.002
(30)
LGE (% mass) was signiﬁcantly higher among those
with inducible VT (22% vs. 10%, p  0.03)
(unadjusted)
(36)
LGE‡ (total scar): pooled OR 2.39 [0.87–6.6], p  0.091 (37)
After adjusting for traditional risk factors for SCD, LGE
(total scar): OR 1.25/5% increase, p  0.002
(38)
LGE‡ (total scar): pooled OR 2.92 [1.01–8.4], p  0.047 (37)
CPH model adjusted for LVEF and LV mass LGE (total
scar): HR: 8.6, p  0.038
(39)
CPH model adjusted for EF, EDV, NYHA class, and LGE
LGE: HR: 12.8, p  0.01 for cardiac mortality No
SCD for those with LGE (NPV 100%). HR: could
not be calculated
(41)
10/10 patients with h/o VT had LGE CPH model, EF
40% was the only independent predictor of
all-cause death and SCD
(44)
Unadjusted odds LGE: OR 11.5, p  0.05 (47)
 Ventricular stimulation test: higher event rate:
75% (2 death, 4 SCD) vs. 1.5%, p  0.0001
(48)
gory); †secondary endpoint; ‡meta-analysis of 4 studies.
entricle; NPV  negative predictive value; NA  not available; OR  odds ratio;Table 3. Summary of M
Cohort
DCM
HCM
Viral Myocarditis
Chagas
Sarcoidosis
*Study included nonischem cate
HCM  hypertrophic card eft vdefined.
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397Chagas. Chagas disease is an infectious process
caused by Trypanosoma cruzi that affects the LV
myocardium, leading to inflammation and fibrosis
(Fig. 6) (43), and is an important cause of heart
failure and perhaps SCD in South America. In a
study of 56 patients without an ICD, LVEF 40%
was the only independent predictor of SCD (HR:
6.58, p  0.0005) (44). LGE might be present in
up to 69% of patients with disease and 100% of
those with history of VT (45). However, the prog-
nostic value of LGE in predicting SCD in Chagas
disease remains unknown.
Sarcoidosis. Sarcoidosis is a granulomatous disease
that might infiltrate the heart and cause LV dys-
Figure 1. Applications of CMR in Imaging Patients at Risk for S
The ﬁgure illustrates different imaging techniques and applications
(SCD): 1) assessing ventricular volumes and ejection fraction (EF) (to
curve [B] that generates EF); 2) evaluating the presence of scar, inte
row illustrating acute myocardial infarction with late gadolinium en
arrows, D], and T2-mapping to quantitate tissue edema [black arro
asymmetrical thickening of the interventricular septum on a cine im
enhancement [asterisks, G], and T1-mapping [H] that allows quant
mon cause of SCD in athletes (bottom row showing anomalous ori
left main (LM) artery from the noncoronary cusp (NCC) [J]). LAD 
and G are reproduced with permission from Verhaert et al. (97).function, scar, and arrhythmias (46). LGE onCMR (Fig. 7) is twice as sensitive as current
consensus criteria in detecting cardiac involvement
(47). Patel et al. (47) showed that patients with
sarcoidosis and LGE had a 9-fold higher rate of
adverse events and 11.5-fold higher unadjusted rate
of cardiac death than those without LGE. Al-
though the LVEF was lower for patients with LGE
(median 45% vs. 56% for the study cohort), it was
higher than the guidelines criteria for ICD insertions
(47). These findings should fuel more research; how-
ever, with only 5 cardiac deaths and 2 SCDs in that
study, it is hard for these results to change the
guidelines. In patients with biopsy-proven cardiac
sarcoidosis undergoing programmed ventricular stim-
ardiac magnetic resonance (CMR) to stratify patients at risk for sudde
ow showing automated tracing of ventricular volumes [A] and corres
tial ﬁbrosis, and tissue edema in patients with ischemic cardiomyopa
cement [pink arrows, C], tissue edema on T2–short tau inversion rec
E]), and patients with hypertrophic cardiomyopathy (HCM) (third row
ng at end-diastole of a patient with HCM [F], presence of scar on late
ion of interstitial ﬁbrosis); and 3) assessing anomalous coronary arter
of the right coronary artery from the left coronary cusp [I] and anom
anterior descending coronary artery; LCx  left circumﬂex coronary aCD
of c n cardiac death
p r ponding volume
rsti thy (ICM) (second
han overy [STIR] [yellow
ws, illustrating severe
agi gadolinium
iﬁcat ies, which is a com-
gin alous origin of the
left rtery. Panels C, D, E,ulation, those who were inducible had higher ventric-
C
w
s
a
(
a
(
V
i
(
rsion
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398ular arrhythmia or death (6 of 8 vs. 1 of 68, p 
0.0001) (48). Similar findings were described by Aizer
et al. (49). Although LGE allows earlier detection
and identification of cardiac involvement, the
association with SCD and risk-stratification be-
yond LVEF remains ill-defined. The current
practice is to implant an ICD in patients with
cardiac sarcoidosis who exhibit ventricular ar-
rhythmia or symptoms such as syncope, irrespec-
tive of scar on CMR. Whether CMR can guide
physicians in making therapeutic decision for
primary prevention on the basis of LGE remains
to be determined. Also, LGE might signify
gadolinium retention due to edema and active
inflammation rather than scar and, not uncom-
monly, might regress after treatment (50).
Hence, risk assessment on the basis of initial scan
might be inadequate.
Role of CMR in predicting SCD in other car-
diomyopathies. There is an increasing role for
MR in other cardiomyopathies (Figs. 7 and 8) but
ith limited evidence with regard to risk-
tratification for SCD.
CMR plays an important role in the diagnosis of
rrhythmogenic ventricular dysplasia (ARVD) (Fig. 7)
51), which is associated with a high prevalence of
ppropriate ICD therapy and SCD reaching 48%
Figure 2. CMR in Ischemic Cardiomyopathy
The ﬁgure illustrates cardiac magnetic resonance (CMR) in a patient
gadolinium enhancement (LGE) (A and B) with microvascular obstr
was also evidence of signiﬁcant tissue edema on T2–short tau inve52). The presence of LGE is a marker of inducibleT in 75% of patients (6 of 8), whereas its absence
s associated with no inducible arrhythmia (0 of 4)
p  0.01) (53). Identification of RV scar on LGE,
however, is challenging with a dilated RV and
aneurysmal walls. In clinical practice, most patients
with ARVD receive an ICD irrespective of the
LGE results.
The presence of diffuse LGE with particular Gd
kinetics in patients with suspected cardiac amyloid-
osis confirms the diagnosis (Fig. 7) and provides
prognostic information with regard to cardiac
death (54). Although the incidence of SCD in
cardiac amyloidosis might range from 15% to
25% (55,56), the correlation between scar and
SCD is not defined.
Cardiac siderosis, by contrast, is associated with
myocardial iron overload. Due to the ferromagnetic
properties of the iron, the myocardium will have
low SI (Fig. 7), and the amount of iron/gram tissue
can be quantitated with T2* (57). In 652 thalasse-
mia major patients, cardiac T2* 20 ms (as com-
pared with 20 ms) was associated with increased
risk for arrhythmia (relative risk: 4.6, 95% CI: 2.66
to 7.95) (58).
Anderson-Fabry disease is a lysosomal storage
disease characterized by increased LV wall thick-
h acute myocardial infarction and evidence of transmural late
n (arrows, A). The extent of LGE was traced manually (B); there
recovery imaging (asterisk, C).wit
uctioness (due to buildup of glycolipids), sometimes in
layed enhancement (bottom row).
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399an asymmetrical pattern mimicking HCM. Late
gadolinium enhancement occurs in 50% of patients
in the basal inferolateral wall (Fig. 7) and correlates
with focal collagen scarring, which is thought to
trigger arrhythmia (59). Similarly, Duchenne and
Becker muscular dystrophies are neuromuscular dis-
eases associated with myocardial fibrosis (Fig. 7)
(60–62), a potential substrate for ventricular ar-
rhythmias that increase in burden with worsening
of myocardial involvement (63). The role of CMR
in risk-stratifying patients, however, remains poorly
defined in all of these diseases.
Postpartum and Takotsubo cardiomyopathies are
often transient in nature and not uncommonly
associated with LGE, which might be due to
myocardial necrosis (myocarditis-like mechanism or
less commonly coronary artery dissection) (64) or
Gd retention secondary to extracellular matrix ex-
pansion, respectively. Although ventricular arrhyth-
mias have been reported in either condition (65,66),
the presence of LGE was not associated with worse
outcomes in Takotsubo cardiomyopathy (67) and
with limited data in postpartum cardiomyopathy
(68).
Athletes. SCD affects approximately 1 of 100,000
athletes/year (69). CAD is the most common cause
among those over 35 years of age (70), whereas
Figure 3. CMR in Dilated Cardiomyopathy
The ﬁgure illustrates cardiac magnetic resonance (CMR) performed
tricle was dilated with signiﬁcantly and globally reduced systolic fu
row). On late gadolinium (Gd) imaging, there was no signiﬁcant deon a patient with nonischemic dilated cardiomyopathy. The left ven-
nction (cine images with end-diastolic and end-systolic frames, topHCM (26%), anomalous coronary artery (14%),Figure 4. CMR in HCM
The ﬁgure illustrates cardiac magnetic resonance (CMR) in a symptomatic
patient with hypertrophic cardiomyopathy (HCM) with asymmetrical hyper-
trophy and interventricular septal wall thickness of 3.2 cm (top row, aster-
isk) and signiﬁcant scar of delayed imaging post-gadolinium (Gd) injection
(bottom row, arrow). Patient subsequently underwent myomectomy and
implantable cardiac deﬁbrillator placement for primary prevention. Two
months later, he had appropriate implantable cardiac deﬁbrillator ﬁring.
e ep
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400and ARVD (22% in Italy) are most common in
those younger than 35 years (70,71). The role of
CMR in identifying athletes at risk for SCD has
been evaluated previously (71). Anomalous coro-
nary arteries such as left main originating from the
right sinus of Valsalva with interarterial course and
anomalous right coronary from the left sinus have
been associated with SCD (71). CMR with
3-dimensional angiography provides anatomical
images of the origin and proximal course of the
coronary arteries but lacks the spatial resolution and
border definition of cardiac computed tomography
and requires 5 to 10 min of free-breathing imaging-
time but without the need for contrast or radiation.
Although surgical intervention is often performed
when dealing with such “malignant anomalous
coronary arteries,” recent publication showed that
surgery offered no survival benefit (72). Finally,
positive cardiac enzymes among athletes after mar-
athon running have been described and were pre-
sumed to be secondary to myocardial necrosis with
potential link to SCD. However, recent study
showed absence of LGE and concluded that the
increase in cardiac troponin was due to cytosolic
Figure 5. CMR in Myocarditis
The ﬁgure illustrates cardiac magnetic resonance (CMR) in a patient
(even on cine imaging post-Gd injection, arrows, top row) on late
was in a noncoronary artery distribution and most prominent in threlease rather than necrosis (73).Non-CMR Techniques and
Risk Stratification for SCD
Noninvasive and less costly testing have shown
promising results in small studies in risk-stratifying
patients for SCD and included: QRS duration,
Selvester QRS score (74), QT dispersion, signal
averaging, heart rate variability, heart rate recovery,
heart rate turbulence, exercise functional capacity,
T-wave alternans, Holter monitor, and barorecep-
tor sensitivity (75). However, the clinical utility of
these tests to guide selection of therapy were either
not performed or showed inconsistent results (75).
Echocardiography and nuclear cardiac imaging
have important roles in risk-stratifying patients for
SCD, beyond LVEF, volumes, and LV mass. For
instance, there is an increasing role for radial and
global longitudinal strain in identifying cardiac
sarcoidosis (76), risk-stratifying patients with CAD
(77), HCM (78), or systemic sclerosis (79) for
ventricular arrhythmia or cardiac death. In nuclear
imaging, the extent of perfusion defect size on
single photon emission computed tomography adds
incremental prognostic value when stratifying for
h myocarditis with evidence of signiﬁcant gadolinium (Gd) uptake
linium enhancement (LGE) (arrows, bottom row). The Gd uptake
icardial distribution with sparing of the endocardium.wit
gadocardiac death (80). Also, mechanical dyssynchrony
rose
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401index from phase analysis of gated single photon
emission computed tomography predicts ICD ther-
apy or death (81). Furthermore, new emerging data
with cardiac positron emission tomography in
evaluating scar and inflammation in cardiac sar-
coidosis might prove useful for predicting ar-
rhythmia (82). CMR has limited ability to assess
cardiac sympathetic denervation, which plays an
important role in ventricular arrhythmia (83).
Indeed, 123-I metaiodobenzyl-guanidine imaging
was shown to be a strong predictor for SCD and
appropriate ICD therapy, outperforming other
noninvasive markers (83). Perhaps the future re-
sides in hybrid magnetic resonance imaging (MRI)/
nuclear imaging for optimal risk stratification, al-
though not U.S. Food and Drug Administration
approved yet and with a nontrivial radiation burden.
Strengths, Limitations, and Future Directions
CMR is a noninvasive imaging modality that as-
sesses ventricular volumes and function, proximal
coronary arteries, and myocardial scar (Table 1) and
risk-stratifies patients (Table 2). The study is usu-
ally performed in 40 min without radiation
burden.
Although the role of CMR in risk-stratifying for
Figure 6. CMR in Chagas Disease
This is a patient from South America presenting with heart failure a
demonstrates wall motion abnormality in the basal inferolateral wa
dial and mid-myocardial inferolateral wall as well as epicardial anteSCD has been evaluated in multiple studies, thenumber of patients and events were low even in
common diseases such as ICM, DCM, and HCM,
which raises major criticism and limits the power of
the studies. The role of CMR in less common
cardiomyopathies is even more problematic. In
addition, all evidence was derived from retrospec-
tive or observational studies. One of the few ran-
domized clinical trials—DETERMINE (Defibril-
lators to Reduce Risk by Magnetic Resonance
Imaging Evaluation) study—has been prematurely
terminated due to poor enrollment (84). In the
absence of randomized trials, meta-analysis is the
second-best evidence; however, there is only 1 such
study with HCM and with still low number of
events (37). The different study designs and out-
comes in ICM and DCM have precluded such
meta-analysis. Furthermore, there is a lack of trials
specifically designed to prospectively test the value
of CMR-guided strategy, which is a necessary step
before the implementation of guideline changes.
Furthermore, VT, inducible ventricular arrhyth-
mia, appropriate ICD therapy or shock, and sudden
cardiac arrest were all primary or secondary out-
comes that were used and, although similar, are not
surrogate for SCD nor interchangeable (85). Fi-
nally, the risk for SCD is not static; patients might
have worsening of their condition and new insults
found to have Chagas disease: cardiac magnetic resonance (CMR)
and asterisk, B) and late gadolinium enhancement in the epicar-
ptal wall (C, arrows). ED  end-diastole; ES  end-systole.nd
ll (Aover time, whereas others might have significant
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402recovery or improvement (85). Hence, assessment
on the basis of first imaging alone might not be
accurate, and follow-up evaluation might be
warranted.
The cost-effectiveness of CMR remains to be
assessed. The long-term follow-up results from the
MADIT II trial (Multicenter Automatic Defibrillator
Implantation Trial) showed that the number of ICD
needed to be implanted to save 1 life was 8 (86); such
a number is hard to beat and justify additional costly
testing. However, one-third of patients actually re-
ceive an appropriate shock (approximately 5%/
Figure 7. CMR in Inﬁltrative and Neuromuscular Cardiomyopath
Cardiac magnetic resonance imaging demonstrating different types
presenting with arrhythmia and found to have cardiac involvement
B, arrows); 2) arrhythmogenic ventricular dysplasia (ARVD) with dila
kinetic/aneurysmal focal wall motion (arrow, D), and LGE of the RV
that was conﬁrmed with CMR with increased left ventricular thickne
involving the liver and myocardium with signiﬁcant decrease in cor
compared with a healthy control subject (I); 5) patient with Duchen
abnormality in the lateral wall (J and K, arrow) with corresponding
Figures 2 and 6.year for the primary prevention group during thetrial follow-up time) (2). Although patients with
poor LV function have the highest risk for SCD,
the majority of events occur in patients with
normal LV function (87); therefore, there is need
for more robust risk-stratification for SCD.
There is also new evidence that inappropriate
ICD shocks are associated with increased all-
cause mortality, which highlights the need for
better patient selection (88).
Although CMR assessment of scar by LGE is an
extremely robust technique, it has several limitations,
including partial volume effect (89), post-processing
ardiomyopathy: 1) patient with known pulmonary sarcoidosis
ted is the diffuse LGE in a noncoronary artery distribution, A and
right ventricle (RV) (C and D), impaired RV systolic function, dys-
wall (arrow, E); 3) patient with suspected cardiac amyloidosis
F) and diffuse LGE (asterisks, G); 4) patient with hemochromatosis
onding tissue signal intensity on cine imaging (asterisks, H) as
muscular dystrophy and cardiac involvement with wall motion
cardial and mid-myocardial LGE (arrow, L). Abbreviations as iny
of c
(no
ted
free
ss (
resp
ne
epitime, and different quantification techniques (14–16).
a
s
t
p
d
l
p
m
a
C
i
i
D
s
ance
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 3 , 2 0 1 3
M A R C H 2 0 1 3 : 3 9 2 – 4 0 6
AlJaroudi et al.
CMR and Sudden Cardiac Death
403There is no consensus on a uniform threshold, partic-
ularly for peri-infarct quantification, which is highly
dependent on spatial resolution (90), and as such its
predictive value remains controversial (20). This is
important, because more studies are showing that the
extent of scar is a more important prognostic marker
than a simple present/absent, and as such quantifica-
tion will be necessary in future studies.
Assessment of viability requires administration of
Gd. However, in patients with significant renal
impairment, Gd administration should be avoided
(unless no other alternative is available), because of
nephrogenic sclerosing fibrosis risk (91). Pre-
contrast T1 mapping has emerged as a new alter-
native technology that detects pathological myocar-
dial tissue and interstitial fibrosis on the basis of T1
characteristics without the need for contrast. Such
abnormalities might be present before scar on LGE
and prove useful in early identification of cardiomy-
opathies and risk-stratification in less symptomatic
patients. The technique is not without limitation
nd is not yet commercially available but has been
howing good potential (8). Taking advantage of
he different tissue characteristics of normal versus
athological myocardial tissue, T1-mapping can
elineate abnormal areas and quantify them with
ess variability than other techniques. It can also be
erformed post-Gd administration (post-contrast
apping) (10,92). Also, additional techniques such
s feature tracking, tagged CMR, or strain encoded
MR assess regional myocardial strain heterogene-
ty and might implicate regions of fibrosis. In
Figure 8. CMR in Postpartum Cardiomyopathy
The ﬁgure illustrates focal wall motion abnormality at end-systole (
tole (ED) (A and B) with corresponding area of late gadolinium enh
absence of coronary artery disease. CMR  cardiac magnetic resonCMR was shown to predict clinical outcomes (93)
and is a promising technique, particularly because it
does not necessitate Gd administration.
Finally, the application of CMR in patients with
pacemakers or ICD remains contraindicated. Al-
though recent advances in technology have resulted
in MRI-compatible devices, only noncardiac MRI
studies are approved with such devices. Still, several
centers are performing CMR (1.5-T) in patients
with MRI-compatible devices as long as patients
are not device-dependent and have device interro-
gation pre- and post-CMR with an electrophysiol-
ogy physician on site during the study (94–96). The
application of CMR with ICD at 3.0-T has not
been tested yet and remains contraindicated.
Conclusions
CMR is a noninvasive imaging modality that visu-
alizes and quantifies scar and with growing evidence
delineating its additive value in identifying patients
at risk for SCD. Although implementing changes
in the guidelines might be premature, given the
current level of evidence, larger and adequately
powered studies designed to prospectively test the
value of CMR-guided strategy with uniform and
well-accepted endpoints are needed.
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